Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
Sign Up to like & getrecommendations! Published in 2021 at "Lung Cancer: Targets and Therapy"
DOI: 10.2147/lctt.s305466
Abstract: Abstract Immunocheckpoint inhibitors (ICIs) have altered the treatment landscape of a wide range of malignancies, including non–small cell lung cancer (NSCLC). This class of agents inhibits the interaction between PD1 and PDL1, and was shown… read more here.
Keywords: nsclc durvalumab; stage iii; durvalumab; iii nsclc ... See more keywords